[1] 赵泽华, 刘晓琳, 范建高. 重视非酒精性脂肪性肝病自然史的研究. 中华肝脏病杂志, 2017, 25(2):81-84. [2] Perazzo H, Dufour JF . The therapeutic landscape of non-alcoholic steatohepatitis. Liver Int, 2017, 37(5):634-647. [3] Bedossa P . Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential. Liver Int, 2018, 38(1):64-66. [4] 曾静, 黄丽素, 潘勤, 等. 瞬时弹性成像用于上海学龄前体检儿童肝脏硬度及脂肪定量检测研究. 中华实用儿科临床杂志, 2018, 33(19):1483-1485. [5] Karlas T , Petroff D , Sasso M , et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol, 2017, 66(5):1022-1030. [6] Vuille-Lessard É, Lebouché B, Lennox L , et al. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. AIDS, 2016, 30(17):2635-2643. [7] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版). 中华肝脏病杂志, 2010, 18(3):163-166. [8] Hameed B , Terrault NA , Gill RM , et al. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.Aliment Pharmacol Ther, 2018, 47(5):645-656. [9] Shah AS , Khan S , Rahim H , et al. Prevalence of non alcoholic fatty liver and Non alcoholic steatohepatitis in Peshawar Cantonment, Khyber Pakhtunkhwa, Pakistan.Pak J Pharm Sci, 2018, 31(1):193-198. [10] Wang L , Guo J , Lu J . Risk factor compositions of nonalcoholic fatty liver disease change with body mass index in males andfemales. Oncotarget, 2016, 7(24):35632-35642. [11] Petta S, Wong VW, Cammà C, et al. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. Hepatology, 2017, 65(4):1145-1155. [12] van Katwyk S, Coyle D, Cooper C , et al. Transient elastography for the diagnosis of liver fibrosis: a systematic review of economic evaluations. Liver Int, 2017, 37(6):851-861. [13] Papapostoli I , Lammert F , Stokes CS . Effect of short-term vitamin D correction on hepatic steatosis as quantified by controlled attenuation parameter (CAP).J Gastrointestin Liver Dis, 2016, 25(2):175-181. [14] Ferraioli G , Tinelli C , Lissandrin R , et al. Correlation of the controlled attenuation parameter with indices of liver steatosis in overweight or obese individuals. Eur J Gastroenterol Hepatol, 2015, 27(3):305-312. [15] 沈峰, 郑瑞丹, 宓余强, 等. 细胞角蛋白-18联合受控衰减参数二步法无创鉴别非酒精性脂肪性肝炎的临床研究. 中华肝脏病杂志, 2016, 24(6):429-434. [16] 徐亮, 李萍, 陆伟,等. FibroScan © 实施受控衰减参数诊断脂肪肝的价值. 中华肝脏病杂志, 2016, 24(2):108-113. [17] Chan WK, Nik Mustapha NR, Wong GL , et al. Controlled attenuation parameter using the FibroScan © XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. Unit Eur Gastroenterol J, 2017, 5(1):76-85. [18] Shousha HI , Abdelaziz RA , Azab SM , et al. Effect of treatment with direct acting antivirals on body mass index and hepatic steatosis in chronic hepatitis C.J Med Virol, 2018, 90(6):1099-1105. [19] Vuppalanchi R, Siddiqui MS, Van Natta ML , et al. Performance characteristics of vibration‐controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology, 2018, 67(1):134-144. [20] Bakulin IG , Sandler YG , Keyan VA , et al. A new non-invasive method for assessing steatosis in chronic liver diseases.Ter Arkh, 2016, 88(2):49-57. |